NEXLIZET
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $946,128 | 1,306 | 594 |
| 2023 | $197,812 | 379 | 258 |
| 2022 | $2.0M | 4,754 | 2,704 |
| 2021 | $5.0M | 12,427 | 6,874 |
| 2020 | $1.7M | 2,925 | 1,537 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.4M | 3,560 | 75.3% |
| Food and Beverage | $1.4M | 16,318 | 14.7% |
| Travel and Lodging | $767,985 | 1,857 | 7.9% |
| Unspecified | $143,000 | 2 | 1.5% |
| Consulting Fee | $44,911 | 17 | 0.5% |
| Honoraria | $15,300 | 6 | 0.2% |
| Education | $1,323 | 31 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Predicting 10-year risk of cardiovascular events in Baylor Scott & White Cardiology Patients with Established Cardiovascular Disease | Esperion Therapeutics, Inc. | $143,000 | 0 |
Top Doctors Receiving Payments for NEXLIZET — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Cardiovascular Disease | Manassas, VA | $70,011 | 62 |
| , MD | Cardiovascular Disease | Southaven, MS | $69,581 | 77 |
| , MD | Cardiovascular Disease | Grapevine, TX | $67,313 | 59 |
| , MD | Cardiovascular Disease | Lexington, KY | $64,299 | 59 |
| , MD | Internal Medicine | New York, NY | $63,871 | 52 |
| , MD FACC FSCAI FSVM | Interventional Cardiology | Lexington, KY | $61,099 | 48 |
| , M.D | Cardiovascular Disease | Hialeah, FL | $60,370 | 56 |
| , MD | Cardiovascular Disease | Pgh, PA | $59,358 | 67 |
| , MD | Interventional Cardiology | Longwood, FL | $58,917 | 57 |
| , MD | Cardiovascular Disease | Las Vegas, NV | $57,464 | 54 |
| , MD | Cardiovascular Disease | Haddon Heights, NJ | $56,705 | 49 |
| , MD | Cardiovascular Disease | San Antonio, TX | $54,474 | 64 |
| , MD | Cardiovascular Disease | Atlanta, GA | $54,344 | 41 |
| , MD | Cardiovascular Disease | Houston, TX | $52,850 | 54 |
| , M.D | Specialist | Webster, TX | $52,627 | 49 |
| , M.D | Cardiovascular Disease | Houston, TX | $49,597 | 54 |
| , M.D | Internal Medicine | Kansas City, MO | $49,570 | 42 |
| , M.D | Internal Medicine | Charlotte, NC | $49,516 | 51 |
| , MD | Interventional Cardiology | Hasbrouck Heights, NJ | $48,184 | 53 |
| , D.O | Internal Medicine | Encino, CA | $48,024 | 51 |
| , M.D. FACP | Internal Medicine | Kensington, MD | $47,996 | 52 |
| , PA | Physician Assistant | Hazard, KY | $47,125 | 76 |
| , M.D | Family Medicine | Sterling, IL | $46,110 | 31 |
| , MD | Internal Medicine | Detroit, MI | $45,437 | 33 |
| , D.O | Internal Medicine | York, PA | $43,803 | 49 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $9.8M
- Total Doctors 10,010
- Transactions 21,791
About NEXLIZET
NEXLIZET is a drug associated with $9.8M in payments to 10,010 healthcare providers, recorded across 21,791 transactions in the CMS Open Payments database. The primary manufacturer is Esperion Therapeutics, Inc..
Payment data is available from 2020 to 2024. In 2024, $946,128 was paid across 1,306 transactions to 594 doctors.
The most common payment nature for NEXLIZET is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($7.4M, 75.3% of total).
NEXLIZET is associated with 1 research study, including "Predicting 10-year risk of cardiovascular events in Baylor Scott & White Cardiology Patients with Established Cardiovascular Disease" ($143,000).